• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    2/13/24 4:59:02 PM ET
    $BCPC
    Major Chemicals
    Industrials
    Get the next $BCPC alert in real time by email
    SC 13G/A 1 tv0397-balchemcorp.htm SCHEDULE 13G/A balchemcorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 13)*

    Name of issuer:  Balchem Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  057665200

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  057665200

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    59,244

    7.  SOLE DISPOSITIVE POWER

    3,698,113

    8.  SHARED DISPOSITIVE POWER

    93,399

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,791,512

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.76%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Balchem Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5 Paragon Drive
    Montvale, NJ 07645

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    057665200

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $BCPC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCPC

    DatePrice TargetRatingAnalyst
    3/8/2022$170.00 → $155.00Buy
    HC Wainwright & Co.
    2/22/2022$175.00Neutral → Buy
    Sidoti
    1/10/2022$160.00 → $170.00Buy
    HC Wainwright & Co.
    11/29/2021$175.00Buy → Neutral
    Sidoti
    8/2/2021$140.00 → $145.00Overweight → Equal-Weight
    Stephens & Co.
    8/2/2021$145.00 → $160.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCPC
    SEC Filings

    View All

    SEC Form 10-Q filed by Balchem Corporation

    10-Q - BALCHEM CORP (0000009326) (Filer)

    7/31/25 4:17:29 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BALCHEM CORP (0000009326) (Filer)

    7/31/25 7:17:48 AM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form 11-K filed by Balchem Corporation

    11-K - BALCHEM CORP (0000009326) (Filer)

    6/24/25 4:38:30 PM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Balchem with a new price target

    HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously

    3/8/22 6:19:56 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem upgraded by Sidoti with a new price target

    Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00

    2/22/22 8:56:13 AM ET
    $BCPC
    Major Chemicals
    Industrials

    HC Wainwright & Co. reiterated coverage on Balchem with a new price target

    HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously

    1/10/22 6:15:56 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO, & Secretary Miyata Hatsuki covered exercise/tax liability with 483 shares, decreasing direct ownership by 7% to 6,189 units (SEC Form 4)

    4 - BALCHEM CORP (0000009326) (Issuer)

    7/28/25 6:15:00 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SVP and GM, Specialty Products Van Gunsteren Job Leonard was granted 2,128 shares and covered exercise/tax liability with 964 shares, increasing direct ownership by 14% to 9,446 units (SEC Form 4)

    4/A - BALCHEM CORP (0000009326) (Issuer)

    4/11/25 7:11:10 PM ET
    $BCPC
    Major Chemicals
    Industrials

    Amendment: SVP & Chief HR Officer Tignor Michael Brent was granted 3,497 shares and covered exercise/tax liability with 1,156 shares, increasing direct ownership by 35% to 9,123 units (SEC Form 4)

    4/A - BALCHEM CORP (0000009326) (Issuer)

    4/11/25 6:43:35 PM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Financials

    Live finance-specific insights

    View All

    Balchem Corporation Reports Second Quarter 2025 Financial Results

    MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor

    7/31/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

    MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch

    7/17/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Reports First Quarter 2025 Financial Results

    MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o

    4/24/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Balchem Corporation

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    11/13/24 6:56:07 PM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    2/13/24 4:59:02 PM ET
    $BCPC
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Balchem Corporation (Amendment)

    SC 13G/A - BALCHEM CORP (0000009326) (Subject)

    2/9/24 11:29:17 AM ET
    $BCPC
    Major Chemicals
    Industrials

    $BCPC
    Leadership Updates

    Live Leadership Updates

    View All

    AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

    BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

    8/16/21 8:00:00 AM ET
    $AZRX
    $BCPC
    $BDSI
    Major Pharmaceuticals
    Health Care
    Major Chemicals
    Industrials

    $BCPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Balchem Corporation Reports Second Quarter 2025 Financial Results

    MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, "The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives." Second Quarter 2025 Financial Highlights: Recor

    7/31/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

    MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Second quarter results will be published prior to the market opening on Thursday, July 31, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. To improve the quality of both the live and recorded audio for our conference calls, we have ch

    7/17/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials

    Balchem Corporation to Present at the CJS Annual New Ideas Summer Conference on July 10, 2025

    MONTVALE, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the CJS Annual New Ideas Summer Conference on July 10, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest qual

    6/26/25 7:00:00 AM ET
    $BCPC
    Major Chemicals
    Industrials